Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | RBP4 | P02753 | 1/20 | 0.52 |
| ▸ | SCD | O00767 | 4/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618974 | 0.83 | CYP2C9 (0.66) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL29783896 | 0.82 | CYP2C9 (0.68) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL18997024 | 0.80 | HCRTR1 (0.54) | HSD11B1CYP3A4RBP4SCDNPY2R | |
| SCHEMBL4716887 | 0.80 | SCD (0.56) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL13983799 | 0.80 | SCD (0.62) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL10304326 | 0.79 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL23573376 | 0.78 | CYP2C9 (0.64) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL4262448 | 0.78 | CYP2C9 (0.63) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL2006284 | 0.78 | CYP2C9 (0.59) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL3661780 | 0.78 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | CYP2C9 4867/4885CYP2C19 4884/4885HTR2B 4872/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | CYP2C9 4867/4885CYP2C19 4884/4885HTR2B 4872/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | CYP2C9 4867/4885CYP2C19 4884/4885HTR2B 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.